NASDAQ:PHVS - Pharvaris B.V. Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.50
  • Forecasted Upside: 105.81 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$23.08
▼ -2.93 (-11.26%)
1 month | 3 months | 12 months
Get New Pharvaris B.V. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHVS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$47.50
▲ +105.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pharvaris B.V. in the last 3 months. The average price target is $47.50, with a high forecast of $51.00 and a low forecast of $41.00. The average price target represents a 105.81% upside from the last price of $23.08.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Pharvaris B.V..

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2021SVB LeerinkInitiated CoverageOutperform$50.00N/A
i
Rating by J. Schwartz at SVB Leerink LLC
3/8/2021Morgan StanleyReiterated RatingOverweight$51.00N/A
i
3/8/2021OppenheimerInitiated CoverageOutperform$48.00N/A
i
3/8/2021Bank of AmericaInitiated CoverageNeutral$41.00N/A
i
3/2/2021Morgan StanleyInitiated CoverageOverweight$51.00Low
i
3/2/2021OppenheimerInitiated CoverageOutperform$48.00Low
i
3/2/2021SVB LeerinkInitiated CoverageOutperform$50.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
3/2/2021Bank of AmericaInitiated CoverageNeutral$41.00Low
i
(Data available from 4/21/2016 forward)
Pharvaris B.V. logo
Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $23.08
$23.08
$26.02

50 Day Range

MA: $29.90
$25.69
$39.23

52 Week Range

Now: $23.08
$23.03
$42.86

Volume

599 shs

Average Volume

112,007 shs

Market Capitalization

$734.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pharvaris B.V.?

The following Wall Street sell-side analysts have issued research reports on Pharvaris B.V. in the last year: Bank of America Co., Morgan Stanley, Oppenheimer Holdings Inc., and SVB Leerink LLC.
View the latest analyst ratings for PHVS.

What is the current price target for Pharvaris B.V.?

4 Wall Street analysts have set twelve-month price targets for Pharvaris B.V. in the last year. Their average twelve-month price target is $47.50, suggesting a possible upside of 105.8%. Morgan Stanley has the highest price target set, predicting PHVS will reach $51.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $41.00 for Pharvaris B.V. in the next year.
View the latest price targets for PHVS.

What is the current consensus analyst rating for Pharvaris B.V.?

Pharvaris B.V. currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHVS will outperform the market and that investors should add to their positions of Pharvaris B.V..
View the latest ratings for PHVS.

What other companies compete with Pharvaris B.V.?

How do I contact Pharvaris B.V.'s investor relations team?

The company's listed phone number is 31 71 203 6410. The official website for Pharvaris B.V. is www.pharvaris.com.